title: New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
abstract: Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.
authors.affiliation: SC Oncologia Medica asst, Monza H S Gerardo, Italy.
authors.forename: Diego
authors.initials: D
authors.lastname: Cortinovis
authors.affiliation: Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: Vanesa
authors.initials: V
authors.lastname: Gregorc
authors.affiliation: UOSD Pneumologia Oncologica, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy.
authors.forename: Maria Rita
authors.initials: MR
authors.lastname: Migliorino
authors.affiliation: SC Oncologia Medica asst, Monza H S Gerardo, Italy.
authors.forename: Maria Ida
authors.initials: MI
authors.lastname: Abate
authors.affiliation: SC Thoracic Medical Oncology Istituto Nazionale Tumori, "Fondazione G. Pascale"-IRCCS, Napoli, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Manzo
authors.affiliation: Dipartimento di Sanità Pubblica, Università degli Studi di Napoli Federico II, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Malapelle
authors.affiliation: SC Thoracic Medical Oncology Istituto Nazionale Tumori, "Fondazione G. Pascale"-IRCCS, Napoli, Italy. Electronic address: a.morabito@istitutotumori.na.it.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Morabito
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007558:Italy; D008175:Lung Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077143:Docetaxel; D007211:Indoles; D000077594:Nivolumab; D043823:Taxoids; D000096662:Ramucirumab; C000594389:atezolizumab; C582435:pembrolizumab; C530716:nintedanib
keywords: Atezolizumab; Docetaxel; Nintedanib; Nivolumab; Non squamous NSCLC; Pembrolizumab; Ramucirumab; Second line therapy; Therapeutic strategy